• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.奥拉帕利用于早期BRCA阳性卵巢癌的一线治疗：可行吗？可能催生一系列研究的假设。
Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020.
2
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
3
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
4
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.奥拉帕利联合化疗治疗复发性铂类敏感卵巢癌：一项随机 2 期临床试验。
Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.
5
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.奥拉帕利作为 BRCA1-2 突变的复发性铂类敏感卵巢癌患者的维持治疗：真实世界数据和进展后结局。
Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4.
6
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期：一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
7
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.现行策略在高级别浆液性上皮性卵巢癌的靶向治疗中的应用及 BRCA 突变状态的相关性。
J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
8
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.奥拉帕利片剂剂型在卵巢癌患者中的给药：实用指导和预期。
Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28.
9
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?奥拉帕利维持治疗一线卵巢癌：SOLO1 研究是否会颠覆治疗标准？
Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30.
10
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.一项针对BRCA1或BRCA2突变的HER2阴性晚期乳腺癌一线治疗的I期试验，随后进行两个周期卡铂-奥拉帕利联合治疗，然后奥拉帕利单药治疗与卡培他滨对比的随机II期试验（REVIVAL）：一项随机对照试验的研究方案。
Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.

引用本文的文献

1
Ovarian Cancer: Biomarkers and Targeted Therapy.卵巢癌：生物标志物与靶向治疗
Biomedicines. 2021 Jun 18;9(6):693. doi: 10.3390/biomedicines9060693.
2
Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model.个体化异质 3D 上皮肿瘤微环境模型：以卵巢癌为模型。
Acta Biomater. 2021 Sep 15;132:401-420. doi: 10.1016/j.actbio.2021.04.041. Epub 2021 Apr 30.

本文引用的文献

1
Lymphadenectomy in Ovarian Cancer: Is It Still Justified?卵巢癌的淋巴结切除术：是否仍有必要？
Curr Oncol Rep. 2020 Feb 8;22(3):22. doi: 10.1007/s11912-020-0883-2.
2
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
3
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.聚腺苷二磷酸核糖聚合酶抑制剂作为铂类敏感复发性卵巢癌的维持治疗：根据 BRCA 突变状态的随机临床试验更新的荟萃分析。
Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9.
4
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.尼拉帕利联合一线化疗及维持治疗卵巢癌
N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.
5
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
6
Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with mutations: a meta-analysis on randomized controlled trials.奥拉帕利维持治疗对携带特定突变的铂敏感卵巢癌患者的疗效和安全性：一项随机对照试验的荟萃分析
Cancer Manag Res. 2019 Apr 16;11:3061-3078. doi: 10.2147/CMAR.S191107. eCollection 2019.
7
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?BRCA 基因突变状态是否可预测高级别浆液性卵巢癌患者铂类化疗相关血液学毒性？
Gynecol Oncol. 2019 Jul;154(1):138-143. doi: 10.1016/j.ygyno.2019.04.009. Epub 2019 May 9.
8
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.ESMO-ESGO 共识会议关于卵巢癌的建议：病理学和分子生物学，早期和晚期，交界性肿瘤和复发性疾病†。
Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.
9
Fertility preservation in ovarian tumours.卵巢肿瘤中的生育力保存
Ecancermedicalscience. 2018 Dec 6;12:885. doi: 10.3332/ecancer.2018.885. eCollection 2018.
10
Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer.复发性腹膜癌患者的奥拉帕利脱敏治疗
N Engl J Med. 2018 Nov 29;379(22):2176-2177. doi: 10.1056/NEJMc1810168.

奥拉帕利用于早期BRCA阳性卵巢癌的一线治疗：可行吗？可能催生一系列研究的假设。

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.

作者信息

Tomao Federica, Boccia Serena Maria, Sassu Carolina Maria, Chirra Martina, Palaia Innocenza, Petrella Maria Cristina, Di Donato Violante, Colombo Nicoletta, Benedetti Panici Pierluigi

机构信息

Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome,Polyclinic Umberto I, Rome, Italy.

出版信息

Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020.

DOI:10.2147/CMAR.S194874
PMID:32765062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7369298/
Abstract

Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.

摘要

奥拉帕利目前被批准用于对一线化疗有反应的晚期卵巢癌BRCA（乳腺癌相关抗原）突变患者的维持治疗。该药物的使用基于SOLO1研究的数据，该研究观察到使用奥拉帕利治疗的患者疾病进展或死亡风险降低，无进展生存期的中位数延长约36个月。然而，该试验仅招募了晚期卵巢癌患者。本综述的目的是追溯现有数据，以阐明奥拉帕利在新诊断的早期上皮性卵巢癌中的潜在疗效和可行性。